STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

RANOLAZINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
RANOLAZINE	ASPRUZYO SPRINKLE		52005 52006	GPI-14 (32200040003020, 32200040003040)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of chronic angina and meet **ALL** the following criteria?
   - The patient had a trial of or contraindication to ranolazine ER tablets
   - The patient is unable to swallow ranolazine ER tablets
   - The patient had a trial of or contraindication to a nitrate (e.g., nitroglycerin, isosorbide mononitrate, isosorbide dinitrate)

   If yes, **approve for 12 months by GPID or GPI-14 for the requested strength with the following quantity limits:**
   - **500mg: #2 per day.**
   - **1000mg: #2 per day.**

   If no, do not approve.
   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named **RANOLAZINE (Aspruzyo Sprinkle)** requires the following rule(s) be met for approval:
   A. You have chronic angina (a type of heart condition)
   B. You had a trial of or contraindication (harmful for) to ranolazine ER (extended release) tablets
   C. You are unable to swallow ranolazine ER tablets
   D. You had a trial of or contraindication (harmful for) to a nitrate (such as nitroglycerin, isosorbide mononitrate, isosorbide dinitrate)

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE

STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

RANOLAZINE

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Aspruzyo Sprinkle.

REFERENCES

- Aspruzyo Sprinkle [Prescribing Information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; March 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A
Commercial Effective: 10/01/22
Created: 08/22
Client Approval: 09/22
P&T Approval: 07/22